SPHK

Choose Selective SPHK Inhibitors

SPHK Products

  • All (6)
  • SPHK Inhibitors (5)
  • SPHK Activator (1)
  • New SPHK Products
Catalog No. Product Name Information Product Use Citations Product Validations
S0817 SKI-V SKI V is a noncompetitive and potent inhibitor of non-lipid sphingosine kinase with IC50 of 2 μM for GST-hSK. SKI-V also inhibits PI3K with IC50 of 6 μM for hPI3k. SKI-V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P) and induces apoptosis with antitumor activity.
S5989New SKI-178 SKI-178 is a potent inhibitors of sphingosine kinase-1 (SphK1) and SphK2 with IC50 values ranging from ∼500 nM to ∼1 μM depending on AML cell lines.
S7174 Opaganib (ABC294640) Opaganib (ABC294640) is an orally bioavailable and selective sphingosine kinase-2 (SphK2) inhibitor with IC50 of approximately 60 μM. Phase 1/2.
Front Mol Biosci, 2021, 8:598218
J Pharmacol Exp Ther, 2021, 378(3):300-310
Blood, 2020, 9;blood.2020005569
S7176 SKI II SKI II (SphK-I2) is a highly selective and non ATP-competitive sphingosine kinase (SphK) inhibitor with IC50 of 0.5 μM, while exhibiting no inhibitory action on other kinases including PI3K, PKCα and ERK2.
Elife, 2020, 9e60541
Sci Rep, 2020, 10(1):13834
Front Immunol, 2019, 10:1241
S7177 PF-543 PF-543, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform. PF-543 induces apoptosis, necrosis, and autophagy.
J Pharmacol Exp Ther, 2021, 378(3):300-310
Phytother Res, 2021, 10.1002/ptr.7211
Cancer Biol Ther, 2020, 21(9):841-852
S6512 Defensamide (MHP) Defensamide (MHP) is an activator of sphingosine kinase (SPHK1). It can modulate the innate epidermal immune response by potentiating SPHK1 activity and inducing cAMP production.
S0817 SKI-V SKI V is a noncompetitive and potent inhibitor of non-lipid sphingosine kinase with IC50 of 2 μM for GST-hSK. SKI-V also inhibits PI3K with IC50 of 6 μM for hPI3k. SKI-V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P) and induces apoptosis with antitumor activity.
S5989New SKI-178 SKI-178 is a potent inhibitors of sphingosine kinase-1 (SphK1) and SphK2 with IC50 values ranging from ∼500 nM to ∼1 μM depending on AML cell lines.
S7174 Opaganib (ABC294640) Opaganib (ABC294640) is an orally bioavailable and selective sphingosine kinase-2 (SphK2) inhibitor with IC50 of approximately 60 μM. Phase 1/2.
Front Mol Biosci, 2021, 8:598218
J Pharmacol Exp Ther, 2021, 378(3):300-310
Blood, 2020, 9;blood.2020005569
S7176 SKI II SKI II (SphK-I2) is a highly selective and non ATP-competitive sphingosine kinase (SphK) inhibitor with IC50 of 0.5 μM, while exhibiting no inhibitory action on other kinases including PI3K, PKCα and ERK2.
Elife, 2020, 9e60541
Sci Rep, 2020, 10(1):13834
Front Immunol, 2019, 10:1241
S7177 PF-543 PF-543, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform. PF-543 induces apoptosis, necrosis, and autophagy.
J Pharmacol Exp Ther, 2021, 378(3):300-310
Phytother Res, 2021, 10.1002/ptr.7211
Cancer Biol Ther, 2020, 21(9):841-852
S6512 Defensamide (MHP) Defensamide (MHP) is an activator of sphingosine kinase (SPHK1). It can modulate the innate epidermal immune response by potentiating SPHK1 activity and inducing cAMP production.
S5989New SKI-178 SKI-178 is a potent inhibitors of sphingosine kinase-1 (SphK1) and SphK2 with IC50 values ranging from ∼500 nM to ∼1 μM depending on AML cell lines.